Niacin: A lipid polypill?

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 16, 2008, Pages 2911-2920

  Kostner, Karam ^a,b   Gupta, Soneil ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MSD   (Singapore)

Author keywords

Extended release niacin; Flushing; Lipoproteins; Mechanisms; Niacin

Indexed keywords

APOLIPOPROTEIN B; FATTY ACID; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; PLACEBO; SIMVASTATIN;

ACANTHOSIS NIGRICANS; ARTERY INTIMA PROLIFERATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED DRUG RELEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DYSLIPIDEMIA; EXTENDED DRUG RELEASE; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPIGMENTATION; IMMEDIATE DRUG RELEASE; LIPOLYSIS; LIVER TOXICITY; MACULOPAPULAR RASH; MONOTHERAPY; MYOPATHY; SIDE EFFECT; TREATMENT DURATION; URTICARIA;

CHEMISTRY, PHARMACEUTICAL; DRUG TOXICITY; HUMANS; LIPIDS; NIACIN; PROTEINS;

EID: 56749153524     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.16.2911     Document Type: Article

References (48)

1. Kostner KM, Kostner GM. Lipoprotein (a): still an enigma? Curr Opin Lipidol 2002;13(4):391-6
2. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8(6):1245-55
3. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006;103(17):6682-7
4. Kamanna VS, Moti LK. Mechanism of action of niacin. Am J Cardiol 2008;101(8 Suppl 1): B20-6
5. Jones P, Kafonek K, Laurora I, et al. Comparative dose efficacy study of atorvastation versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia. Am J Cardiol 1998;81:582-7
6. Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diab Obes Metab 2005;7:430-8
7. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study. N Engl J Med 1987;317:1237-45
8. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL-C. N Engl J Med 1999;341:410-8
9. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;17(370):1687-97
10. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164(7):697-705
11. Davidson MH. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol 2008;101(Suppl):14B-19B
12. Carlson LA, Oro L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand 1962;172:641-5
13. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963;173:719-22
14. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9(3):352-5
15. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003;278(11):9869-74
16. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003;303(1):364-9
17. Poynten AM, Gan SK, Kriketos AD, et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 2003;52(6):699-704
18. Shepherd J, Packard CJ, Patsch JR, et al. Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979;63(5):858-67
19. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells Implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17(10):2020-8
20. Zhang LH, Meyers CD, Kamanna VS, et al. Niacin inhibits β chain ATP synthase cell surface expression in HepG2 cells Mechanistic implications for raising HDL [abstract]. Artrioscler Thromb Vasc Biol 2006;E-53
21. Sakai T, Kamanna VS, Kashyap ML. Niacin but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001;21(11):1783-9
22. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004;67(3):411-9
23. Grundy SM, Mok HYI, Zech L, et al. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22(1):24-36
24. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol 1999;19(4):1051-9
25. Ganji SH, Tavintharan S, Zhu D, et al. Niacin non-competitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45(10):1835-45
26. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008;101:20B-26B
27. Thoenes M, Oguchi A, Nagamia S. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 2007;61(11):1942-8
28. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345(22):1583-92
29. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110(23):3512-7
30. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER [Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol]: 3. Curr Med Res Opin 2006;22(11):2243-50
31. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease: JAMA 1975;231(4):360-81
32. Benyó Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol 2006;70(6):1844-9
33. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 2005;115:3400-3
34. Stern RH, Spence JD, Freeman DJ, et al. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 1991;50(1):66-70
35. Karas RH, Kashyap M, Knopp R, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008;8(2):69-81
36. Cefali EA, Simmons PD, Stanek EJ, et al. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther 2007;45(2):78-88
37. Dunn RT, Ford MA, Rindone JP, et al. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995;2(7):478-80
38. Oberwittler H, Baccara-Dinet M, Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006;60(6):707-15
39. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol (Suppl) 2007;99(6A):22C-31C
40. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004;2(4):485-501
41. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45(2):185-97
42. Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study). Am J Cardiol 2004;93(3):307-12
43. Elam MB, Hunninghake DB, Davies KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 2000;284(10):1263-70
44. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47(9):1097-104
45. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. The CLAS Study. J Am Med Assoc 1987;257(23):3233-40
46. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The FATS Study. N Engl J Med 1990;323(19):1289-98
47. Cashin-Hemphill L, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990;264:3013-7
48. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12